BioAtla, Inc. (BCAB)

Market Cap	113.03M
Revenue (ttm)	n/a
Net Income (ttm)	-123.46M
Shares Out	48.10M
EPS (ttm)	-2.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	393,327
Open	2.240
Previous Close	2.240
Day's Range	2.240 - 2.380
52-Week Range	1.240 - 4.068
Beta	1.06
Analysts	Strong Buy
Price Target	14.50 (+517.02%)
Earnings Date	May 9, 2024

About BCAB

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of mela...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 16, 2020
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: BCAB

Analyst Forecast

According to 4 analysts, the average rating for BCAB stock is "Strong Buy." The 12-month stock price forecast is $14.5, which is an increase of 517.02% from the latest price.

Price Target

$14.5

(517.02% upside)

Analyst Consensus: Strong Buy